Recombinant human factor IX: Replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B

Blood

Volumn 88, Issue 7, 1996, Pages 2603-2610

  Brinkhous, Kenneth M ^a   Sigman, Jeff L ^b   Read, Marjorie S ^b   Stewart, Paula F ^b   McCarthy, Kyle P ^b   Timony, Gregg A ^b   Leppanen, Scott D ^b   Rup, Bonita J ^b   Keith Jr , James C ^b   Garzone, Pamela D ^b   Schaub, Robert G ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DOG; DRUG EFFECT; HEMOPHILIA B; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 10144234803     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.7.2603.bloodjournal8872603     Document Type: Article

References (64)

1. Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P: Purified factor IX using monoclonal immunoaffinity technique: Clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 79:568, 1992
2. White GC II, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE, Mononine Study Group: Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. Thromb Haemost 73:779, 1995
3. Berntorp E, Bjorkman S, Carlsson M, Lethagen S, Nilsson IM: Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost 70:768, 1993
4. Roberts HR, Eberst ME: Current management of hemophilia B. Hematol Oncol Clin North Am 7:1269, 1993
5. Thompson AR: Factor IX concentrates for clinical use. Semin Thromb Hemost 9:25, 1993
6. Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM: Human coagulation factor IX: Assessment of thrombogenicity in animal models and viral safety. J Lab Clin Med 121:394, 1993
7. Kasper CK, Lusher JM: Recent evolution of clotting factor concentrates for hemophilia A and B: Transfusion Practices Committee. Transfusion 33:422, 1993
8. Choo KH, Gould KG, Rees DJG, Brownlee GG: Molecular cloning of the gene for human anti-hemophilic factor IX. Nature 299:178, 1982
9. Kurachi K, Davie EW: Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA 79:6461, 1982
10. Brinkhous KM: Gene transfer in the hemophilias: Retrospect and prospect. Thromb Res 67:329, 1992
11. Thompson AR: Molecular biology of the hemophilias. Prog Hemost Thromb 10:175, 1991
12. Thompson AR, Palmer TD, Lynch CM, Miller AD: Gene transfer as an approach to cure patients with hemophilia A or B. Curr Stud Hematol Blood Transfus 58:59, 1991
13. Limentani SA, Roth DA, Furie BC, Furie B: Recombinant blood clotting proteins for hemophilia therapy. Semin Thromb Hemost 19:62, 1993
14. Lozier JN, Brinkhous KM: Gene therapy and the hemophilias. JAMA 271:47, 1994
15. Anson DS, Austen DEG, Brownlee GG: Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells. Nature 315:683, 1985
16. Busby S, Kumar A, Joseph M, Halfpap L, Insley M, Berkner K, Kurachi K, Woodbury R: Expression of active human factor IX in transfected cells. Nature 316:271, 1985
17. de la Salle H, Altenburger W, Elkaim R, Dott K, Dieterle A, Drillien R, Cazenave J-P, Tostoshev P, Lecocq J-P: Active γ-carboxylated human factor IX expressed using recombinant DNA techniques. Nature 316:268, 1985
18. Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB: Expression, purification, and characterization of recombinant γ-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 261:9622, 1986
19. Jorgensen MJ, Cantor AB, Furie BC, Brown CL. Shoemaker CB, Furie B: Recognition site directing vitamin K-dependent γ-carboxylation resides on the propeptide of factor IX. Cell 48:185, 1987
20. Galeffi P, Brownlee GG: The propeptide region of clotting factor IX is a signal for a vitamin K dependent carboxylase: Evidence from protein engineering of amino acid -4. Nucleic Acids Res 15:9505, 1987
21. Rabiet MJ, Jorgensen MJ, Furie B, Furie BC: Effect of propeptide mutations on post-translational processing of factor IX: Evidence that β-hydroxylation and γ-carboxylation are independent events. J Biol Chem 262:14895, 1987
22. Soute BA, Balland A, Faure T, de la Salle H, Vermeer C: In vitro carboxylation of a blood coagulation factor IX precursor produced by recombinant-DNA technology. Thromb Haemost 61:238, 1989
23. Harrison S, Clancy B, Brodeur S, Oakes P, Miller D, Drapeau D, Hamilton M, Charlebois T, Leonard M, McCarthy M, Zollner R, Adamson SR: Development of a serum-free process for recombinant factor IX expression in Chinese hamster ovary cells. Thromb Haemost 73:1222, 1995
24. Foster WB, Anagnostopoulos A. Bonam D, Costigan RJ, Knight A, Sterl KS, Switzer MB, Walsh RE: Development of a process for purification of recombinant human factor IX. Blood 86:870a, 1995 (abstr, suppl 1)
25. Rodriques H, Giles K, Sefton L, Griffon V, Duxbury M, Letwin B: Analytical characterization of recombinant human factor IX (rhFIX). Thromb Haemost 73:1206, 1995
26. Keith JC Jr, Ferranti TJ, Misra B, Frederick T, Rup B, McCarthy K, Faulkner R, Bush L, Schaub RG: Evaluation of recombinant human factor IX: Pharmacokinetic studies in the rat and the dog. Thromb Haemost 73:101, 1994
27. Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA: Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci USA 86:10095, 1989
28. Brinkhous KM, Sigman J, Read MS, Stewart P, Rup B, Frederick T, McCarthy K, Timony G, Keith J, Schaub R: Recombinant human factor IX restores normal hemostasis in a canine model of hemophilia B. Blood 84:64a, 1994 (abstr, suppl 1)
29. Brinkhous KM, Sigman J, Read MS, Stewart P, Timony G, McCarthy K, Leppanen S, Rupp B, Keith JC, Schaub RG: The hemostatic and pharmacokinetic response of recombinant human factor IX is similar to plasma-derived human factor IX in the hemophilia B dog. Thromb Haemost 73:428a, 1995
30. Barrow EM, Bullock WR, Graham JB: A study of the carrier state for plasma thromboplastin component (PTC, Christmas factor) deficiency, utilizing a new assay procedure. J Lab Clin Med 55:936, 1959
31. Langdell RD, Wagner RH, Brinkhous KM: Effect of antihemophilic factor on one-stage clotting tests. J Lab Clin Med 41:745, 1953
32. Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, Read MS: Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci USA 82:8752, 1985
33. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J: A more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorrh 34:869, 1975
34. Feldschuh J, Enson Y: Prediction of the normal blood volume: Relation of blood volume to body habitus. Circulation 56:605, 1977
35. Pratt PW: Medical Nursing for Animal Health Technicians (ed 1). Santa Barbara. CA, American Veterinary Publications, 1985, p 329
36. Fraser CM: The Merck Veterinary Manual: A Handbook of Diagnosis, Therapy, and Disease Prevention and Control for the Veterinarian (ed 6). Rahway, NJ, Merck, 1986, p 32
37. Lee ML, Poon W-Y, Kingdon HS: A two-phase linear regression model for biologic half-life data. J Lab Clin Med 115:745, 1990
38. Hoag MS, Johnson FF, Robinson JA, Aggeler PM: Treatment of hemophilia B with a new clotting factor concentrate. N Engl J Med 280:581, 1969
39. Zauber PN, Levin J: Factor IX levels in patients with hemophilia B (Christmas disease) following transfusion with concentrates of factor IX or fresh frozen plasma (FFP). Medicine 56:213, 1977
40. Heldebrant CM, Gomperts ED, Kasper CK, McDougal JS, Friedman AE, Hwang DS, Muchmore E, Jordan S, Miller R, Sergis-Davenport E, Lam W: Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates. Transfusion 25:510, 1985
41. Menache D: Coagulation factor IX concentrate: Properties and clinical investigation. Thromb Haemost 54:282a, 1985
42. Longo G, Cinotti S, Filimberti E, Giustarini G, Messori A, Morfini M, Ferríni PR: Single-dose pharmacokinetics of factor IX evaluated by model-independent methods. Eur J Haematol 39:426, 1987
43. Kohler M, Seifried E, Hellstern P, Pindur G, Miyashita C, Morsdorf S, Fasco F, Wenzel E: In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients: The influence of reagents and standards. Blut 57:341, 1988
44. Kim HC, McMillan CW, White GC, Bergman GE, Saidi P: Clinical experience of a new monoclonal antibody purified factor IX: Half-life, recovery, and safety in patients with hemophilia B. Semin Hematol 27:30S2, 1990
45. Kim HC, Matts L, Eisele J, Czachur M, Saidi P: Monoclonal antibody-purified factor IX: Comparative thrombogenicity to prothrombin complex concentrate. Semin Hematol 28:15S6, 1991
46. Kasper CK, Abramson SB, Goldsmith JC, Herring S: In vivo recovery, half-life and safety of affinity purified solvent-detergent coagulation factor IX. Blood 78:58a, 1991
47. Morfini M, Longo G, Cinotti S, Filimberti E, Messori A, Rafanelli D, Mannucci PM: Comparative single-dose pharmacokinetic study of alphanine vs. prolinine. Thromb Haemost 65:2424a, 1991
48. Goldsmith JC, Kasper CK, Blatt PM, Gomperts ED, Kessler CM, Thompson AR, Herring SW, Novak PL: Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate. Am J Hematol 40:210, 1992
49. Bjorkman S, Carlsson M, Berntorp E: Pharmacokinetics of factor IX in patients with haemophilia B: Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 46:325, 1994
50. Poon M-C, Aledort LM, Anderle K, Kunschak M, Morfini M, Group FIS: Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Transfusion 35:319, 1995
51. Rimon S, Melamed R, Savion N, Scott T, Nawroth PP, Stern DM: Indentification of a factor IX/IXa binding protein on the endothelial cell surface, J Biol Chem 262:6023, 1987
52. Cheung WF, Hamaguchi N, Smith KJ, Stafford DW: The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem 267:20529, 1992
53. Heimark RL, Schwartz SM: Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Comm 11:723, 1983
54. Stern DM, Drillings M, Nossel HL, Hurlet-Jensen A, La-Gamma KS, Owen J: Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci USA 80:4119, 1983
55. Ryan J, Wolitzky B, Heimer E, Lambrose T, Felix A, Tam JP, Huang LH, Nawroth P, Wilner G, Kisiel W, Nelsestuen GL, Stern DM: Structural determinants of the factor IX molecule mediating interaction with the endothelial cell binding site are distinct from those involved in phospholipid binding. J Biol Chem 264:20283, 1989
56. Astermark J, Stenglo J: The epidermal growth factor-like domains of factor IX: Effect on blood clotting and endothelial cell binding of a fragment containing the epidermal growth factor-like domains linked to the γ-carboxyglutamic acid. J Biol Chem 266:2438, 1991
57. Cheung WF, Straight DL, Smith KJ, Lin S-W, Roberts HR, Stafford DW: The role of the epidermal growth factor-1 and hydrophobic stack domains of human factor IX in binding to endothelial cells. J Biol Chem 266:8797, 1991
58. Toomey JR, Smith KJ, Roberts HR, Stafford DW: The endothelial cell binding determinant of human factor IX resides in the γ-carboxyglutamic acid domain. Biochemistry 31:1806, 1992
59. Mayhew M, Handford P, Brownlee GW: The binding of natural variants of human factor IX to endothelial cells. FEBS Lett 341:74, 1994
60. Nilsson IM, Berntorp E, Lofqvist T, Petterson H: Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 232:25, 1992
61. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R: Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 47:113, 1994
62. Furie B, Limentani SA, Rosenfield CG: A practical guide to the evaluation and treatment of hemophilia. Blood 84:3, 1994
63. Yao S-N, Smith KJ, Karachi K: Primary myoblast-mediated gene transfer: Persistent expression of a human factor IX in mice. Gene Therapy 1:99, 1994
64. Evans JP, Watzke HH, Ware JL, Stafford DW, High KA: Molecular cloning of a cDNA encoding canine factor IX. Blood 74:207, 1989